View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 13, 2020updated 04 Sep 2020 1:33pm

Medicago produces viable Covid-19 vaccine candidate

Biopharmaceutical firm Medicago has produced a Virus-Like Particle (VLP) of the novel coronavirus, SARS-CoV-2, marking the first step in COVID-19 vaccine development.

Visit our Covid-19 microsite for the latest coronavirus news, analysis and updates

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

Follow the latest updates of the outbreak on our timeline.

Biopharmaceutical firm Medicago has produced a Virus-Like Particle (VLP) of the novel coronavirus, marking the first step in Covid-19 vaccine development.

The vaccine candidate, produced in 20 days of receiving SARS-CoV-2 gene, will be subjected to preclinical testing for safety and efficacy.

Medicago is planning to launch human trials in July or August.

Furthermore, the company is leveraging its technology platform to develop Covid-19 antibodies in alliance with the Infectious Disease Research Centre at Laval University.

These antibodies should help treat patients infected by the novel coronavirus. The Canadian Institutes for Health Research (CIHR) is partially funding the research.

Medicago CEO Dr Bruce Clark said: “The pace of our initial progress in Covid-19 is attributable to the capability of our plant-based platform, which is able to produce vaccine and antibody solutions to counteract this global public health threat.

“The ability to produce a candidate vaccine within 20 days after obtaining the gene is a critical differentiator for our proven technology. This technology enables scale-up at unprecedented speed to potentially combat Covid-19.”

The company generated a research-grade vaccine candidate against H1N1 in 19 days in 2009. Later in 2012, it produced ten million doses of a monovalent influenza vaccine for the Defense Advanced Research Projects Agency (DARPA) within one month.

In 2015, Medicago also produced an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA).

Related Companies

Free Whitepaper
img

What is the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry?

While wanting to protect the country from being overwhelmed by Omicron, China’s adherence to a Zero-COVID policy is resulting in a significant economic downturn. COVID outbreaks in Shanghai, Beijing and many other Chinese cities will impact 2022’s economic growth as consumers and businesses experience rolling lockdowns, leading to a slowdown in domestic and international supply chains. China’s Zero-COVID policy is having a demonstrable impact on consumer-facing industries. Access GlobalData’s new whitepaper, China in 2022: the impact of China’s Zero-COVID lockdowns on economic activity, consumer goods and the foodservice industry, to examine the current situation in Shanghai and other cities in China, to better understand the worst-affected industry sectors, foodservice in particular, and to explore potential growth opportunities as China recovers. The white paper covers:
  • Which multinational companies have been affected?
  • What is the effect of lockdowns on foodservice?
  • What is the effect of lockdowns on Chinese ports?
  • Spotlight on Shanghai: what is the situation there?
  • How have Chinese consumers reacted?
  • How might the Chinese government react?
  • What are the potential growth opportunities?
by GlobalData
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology